Johns Hopkins School of Medicine

Panbela Provides Business Update and Reports Q2 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.

Key Points: 
  • MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.
  • Poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting in June 2023.
  • Research and development expenses were $4.2 million in the second quarter of 2023, compared to $20.0 million in the second quarter of 2022.
  • Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $5.3 million.

The Gray Foundation Announces $25 Million in New Funding for BRCA-Related Cancer Research

Retrieved on: 
Thursday, August 10, 2023

The Gray Foundation today announced $25 million in funding for 7 research teams to study new approaches for prevention, early detection, and interception of BRCA-related cancers.

Key Points: 
  • The Gray Foundation today announced $25 million in funding for 7 research teams to study new approaches for prevention, early detection, and interception of BRCA-related cancers.
  • The new grants are part of the Foundation’s ongoing Team Science program, which funds innovative BRCA-related collaborative research.
  • The selected multi-institutional, multi-disciplinary teams will commence studies into a variety of topics related to prevention, early detection, and interception.
  • We are inspired to support this cutting-edge research across institutions as we continue to make progress in early detection, prevention, and interception of BRCA-related cancers.”
    With these grants, the Gray Foundation has committed $187 million to supporting BRCA research.

SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation

Retrieved on: 
Thursday, August 3, 2023

SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.

Key Points: 
  • ; and Il Minn, Ph.D., a radiopharmaceutical and theranostics expert; and Cheol-Young Maeng, Ph.D., a biopharmaceutical industry expert.
  • "The Board will work closely with SK Biopharmaceuticals to drive innovation, and further improve patient care and outcomes as the envisioned biotech company."
  • SK Biopharmaceuticals Chief Executive Officer Donghoon Lee said, "We believe the Board will provide SK Biopharmaceuticals profound insights to help the company make faster decision, transform, and navigate uncertainty.
  • He served as the CTO of SK Biopharmaceuticals in 2021.

Solve GNE Raises $2.5 Million, Secures Leading Researchers to Help Develop Cure for HIBM

Retrieved on: 
Monday, July 31, 2023

LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated sponsored research agreements with multiple leading medical researchers to help develop a cure for Hereditary Inclusion Body Myopathy (HIBM).

Key Points: 
  • LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated sponsored research agreements with multiple leading medical researchers to help develop a cure for Hereditary Inclusion Body Myopathy (HIBM).
  • Solve GNE has been actively raising funds to support a consortium of academic and private sector researchers tasked with the development of various gene therapies.
  • Solve GNE has committed to funding experts in HIBM in four leading organizations: Genosera, Gradalis, Johns Hopkins University School of Medicine and Stanford University.
  • Johns Hopkins University School of Medicine researchers spearheaded by Dr. Greg Newby are the recipients of a multi-year grant from Solve GNE.

Nutromics attracts world leaders in the emerging field of DNA-based sensing to join its Biosensor Advisory Board

Retrieved on: 
Friday, July 28, 2023

Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.

Key Points: 
  • Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.
  • The board consists of researchers from Columbia University, University of California, Johns Hopkins, North Carolina State University, and the University of New South Wales.
  • "We've attracted the most acclaimed researchers in the field because we're world leaders in the space of continuous DNA-based sensing," said Nutromics CEO and co-founder Peter Vranes.
  • To achieve this, we need to collaborate with the most experienced experts, and this advisory board represents a major step in that direction."

HEARING AIDS SLOW COGNITIVE DECLINE IN OLDER ADULTS WITH HEARING LOSS AND AT RISK FOR COGNITIVE DECLINE

Retrieved on: 
Tuesday, July 18, 2023

AMSTERDAM, July 18, 2023 /PRNewswire/ -- Results from the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study, the largest randomized, controlled clinical trial of hearing aids for reducing long-term cognitive decline in older adults, were reported for the first time at the Alzheimer's Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online.

Key Points: 
  • Largest clinical trial to investigate whether a hearing loss treatment intervention can reduce risk of cognitive decline.
  • In the study, in a subgroup of older adults with hearing loss who were at higher risk of cognitive decline, using hearing aids for three years cut cognitive decline in half.
  • The ACHIEVE study is a randomized trial of older adults aged 70-84 with untreated hearing loss who were free from substantial cognitive impairment, conducted at four U.S. sites.
  • Findings from the ACHIEVE study suggest that older adults at increased risk for cognitive decline and dementia who also have hearing loss may benefit the most from this hearing intervention within three years.

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

Retrieved on: 
Monday, July 17, 2023

SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO).
  • In this role, Dr. Chu will oversee clinical development of the Company’s diversified portfolio of Probody® therapeutic candidates.
  • “Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • He was previously Chief Medical Officer at Fate Therapeutics, where he oversaw the company’s clinical development strategies of novel immune cell therapies for the treatment of hematologic and solid tumor malignancies.

Lustgarten Foundation Announces the Appointment of Two New Board Members

Retrieved on: 
Thursday, July 13, 2023

WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS. Dr. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. Dr. Penberthy is a visionary engineering leader with extensive expertise in artificial intelligence (AI) and technology, specifically in the healthcare space.

Key Points: 
  • Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS, join the Lustgarten Foundation Board of Directors.
  • WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS , and Scott Penberthy, PhD, MS .
  • "We are honored to welcome Dr. Vickers and Dr. Penberthy to the Lustgarten Foundation Board of Directors," said Linda Tantawi, CEO of the Lustgarten Foundation.
  • "At the Foundation, we firmly believe in the fundamental role of innovative and cutting-edge research in solving the complexities of pancreatic cancer.

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

Retrieved on: 
Thursday, July 13, 2023

SAN DIEGO, July 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Paul Auwaerter, M.D. to its Board of Directors, effective immediately. Dr. Auwaerter brings over three decades of experience in internal medicine and infectious disease to Capricor.

Key Points: 
  • to its Board of Directors, effective immediately.
  • Dr. Auwaerter brings over three decades of experience in internal medicine and infectious disease to Capricor.
  • “I am extremely pleased to welcome Dr. Auwaerter to our Board of Directors,” said Linda Marbán, Ph.D., Capricor’s CEO.
  • in Medicine from Columbia University and also obtained an M.B.A. at the Johns Hopkins University School of Professional Studies in Business and Education.

Analysis of Half a Billion Lipid Tests from Five Continents Reveals Wide Variation of Heart Disease Lipid Risk by Country and Sex

Retrieved on: 
Monday, July 10, 2023

Published in European Heart Journal , the analysis includes globally recognized laboratory markers of cardiovascular disease risk, including levels of total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride.

Key Points: 
  • Published in European Heart Journal , the analysis includes globally recognized laboratory markers of cardiovascular disease risk, including levels of total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride.
  • The World Health Organization (WHO) and clinical practice guidelines in different countries recognize lipid testing’s clinical value.
  • Of these, the highest mean total cholesterol levels were in Austria (5.40 mmol/L, 208.8 mg/dL) and Germany (5.35 mmol/L, 206.9 mg/dL).
  • While the laboratories involved in the analysis are leaders in their respective countries, their laboratory data may not fully represent any particular country or geography.